This is a topic that has been gaining importance in recent years due to the increase in intestinal problems throughout the population, but what does this really mean and what can I do to improve it.
WHAT IS INTESTINAL DYSBIOSIS?
It is a state of imbalance of the intestinal microbiota and microbiome, which is
characterized by the growth (proliferation) of opportunistic bacteria in the tract
intestinal, accompanied by decreased levels of beneficial bacteria.
The main symptoms of dysbiosis can be: abdominal distention,
alteration of intestinal movements, abdominal and joint pain, mental confusion, food sensitivity, allergies and inflammation.
Dysbiosis has been linked to multiple diseases and disorders
gastrointestinal disorders such as Irritable Bowel Syndrome (IBS), Diseases
inflammatory bowel disease (IBD), bacterial overgrowth (SIBO) and even
autoimmune diseases.
Generally its cause is caused by some infection or the use of
antibiotics. In all cases, the intestine is left vulnerable and exposed to
external pathogens, which prevent an adequate immune response and cause symptoms of various kinds.
WHAT IS CAUSING IT?
It is difficult to find a single culprit or even the root of the problem, but we know
There are several situations that can trigger dysbiosis.
● Poor digestion: including low production of stomach acid and enzymes
digestive disorders, accompanied by overeating, can predispose us to a
high number of pathogenic bacteria. On the other hand we have a
poor bile production and flow (such as in people with gallstones,
cholecystectomy or poor methylation level) due to the properties
bile acid antimicrobials.
● Stress: Prolonged physical or mental stress can increase the risk of
low stomach acid production. On the other hand, elevated cortisol
(“stress hormone”) is associated with decreased levels of IgA, which
decreases immune surveillance at the intestinal level.
● Low consumption of dietary fiber: it is very important for the intestine
cleaning it, in addition to eliminating food within the lumen, which
Otherwise, the overproduction of pathogens is encouraged.
● Altered mucosal production: due to different genetic conditions.
● Food poisoning: exposure to contaminated food and water
during trips. The most common pathogens are: Vibrio cholerae, Clostridium
difficile, Shigella, Shiga toxin-producing Escherichia coli (STEC),
rotavirus, norovirus and the Giardia lamblia parasite. This exposure may lead
to a more permanent change in the microbiota.
● Medications: excessive use of antibiotics can affect the flora in the short and
long term. Additionally, it may result from pathogenic colonization,
commonly caused by Salmonella and C. Difficile. On the other hand, inhibitors of
proton pump may also increase the risk of developing
bacterial overgrowth if used long term.
● Slow transit: can cause stasis and retention of fecal matter and
contribute in this way to SIBO. Decreased intestinal motility
It can be caused by excessive sugar consumption, chronic stress,
diabetes, hypothyroidism, scleroderma, among others.
● Compromised immune system.
HOW TO RESTORE THE BALANCE
One of the best options we have is to use prebiotics and probiotics to encourage a diverse approach to gut flora. Beneficial microbiota inhibit the growth of pathogenic bacteria by modulating intestinal pH, producing bacteriocins, and competing for common binding sites on epithelial cells. In this process, resistance to infection against many pathogens, both bacterial and fungal, is conferred.
Certain probiotics can be especially helpful in cases of SIBO, as they
They have an effect on the balance of the intestinal flora. Both Lactobacillus and
Bifidobacteria have demonstrated antimicrobial actions against several pathogens.
Although in many cases due to discomfort it may be necessary to avoid fiber, especially in very damaged intestines, a diet low in FODMAPs is very
prolonged can cause greater intolerance to soluble fibers and greater dysbiosis.
The goal of any treatment should always be for the person to tolerate a diet rich in soluble fiber, containing a high variety of prebiotic fiber. Gradually increasing your intake of pro- and prebiotics can help build tolerance.
Vagus nerve regulation can also be used to increase gastric acid secretion and improve intestinal motility. It can be stimulated with the consumption of probiotics and exercises such as yoga, meditation and deep breathing.
It is also important to obtain dietary support from a professional to reduce
intake of refined carbohydrates, increase the amount of fiber, polyphenols and
Nutrient-rich foods. In addition to limiting the consumption of alcohol and processed foods that can increase dysbiosis.
Do not hesitate to write to us on our social networks or email for more
information and be able to advise you on your case.
With BioCare start to really supplement yourself.
References:
1. Monira S, Alam NH, Suau A, et al. Time course of bacterial diversity in stool samples of malnourished children with
cholera receiving treatment. J Pediatr Gastroenterol Nutr. 2009;48(5):571-578.
doi:10.1097/MPG.0B013E3181831867
2. Wei L, Singh R, Ro S, Ghoshal UC. Gut microbiota dysbiosis in functional gastrointestinal disorders: Underpinning
the symptoms and pathophysiology. JGH Open. 2021;5(9):976. doi:10.1002/JGH3.12528
3. Caminero A, Meisel M, Jabri B, Verdu EF. Mechanisms by which gut microorganisms influence food sensitivities. Nat
Rev Gastroenterol Hepatol. 2019;16(1):7. doi:10.1038/S41575-018-0064-Z
4. Tang Y, Liu S, Shu H, Yanagisawa L, Tao F. Gut microbiota dysbiosis enhances migraine-like pain via TNFα
upregulation. Mol Neurobiol. 2020;57(1):461. doi:10.1007/S12035-019-01721-7
5. Gawałko M, Agbaedeng TA, Saljic A, et al. Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic
mechanisms and potential clinical implications. Cardiovasc Res. 2022;118(11):2415. doi:10.1093/CVR/CVAB292
6. Chey W, Menees S. The gut microbiome and irritable bowel syndrome. F1000Res. 2018;7.
doi:10.12688/F1000RESEARCH.14592.1
7. Fjeldheim Dale H, Arslan Lied G. Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel
syndrome: recent developments and future perspectives. Turk J Med Sci. 2020;50(7):1632. doi:10.3906/SAG-2002-
57
8. Casén C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining
dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42(1):71. doi:10.1111/APT.13236
9. de Oliveira GLV, Leite AZ, Higuchi BS, Gonzaga MI, Mariano VS. Intestinal dysbiosis and probiotic applications in
autoimmune diseases. Immunology. 2017;152(1):1. doi:10.1111/IMM.12765
10. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur
J Clin Invest. 2011;41(4):380-386. doi:10.1111/J.1365-2362.2010.02419.X
11. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile Acids and the Gut Microbiome. Curr Opinion Gastroenterol.
2014;30(3):332. doi:10.1097/MOG.0000000000000057
12. Khaustova SA, Shkurnikov MU, Tonevitsky AG. Short highly intense exercise causes changes in salivary
concentrations of hydrocortisone and secretory IgA. Bull Exp Biol Med. 2010;149(5):635-639. doi:10.1007/S10517-
010-1012-2
13. Desai MS, Seekatz AM, Koropatkin NM, et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus
Barrier and Enhances Pathogen Susceptibility. Cell. 2016;167(5):1339–1353.e21. doi:10.1016/j.cell.2016.10.043
14. Juge N. Microbial adhesins to gastrointestinal mucus. Trends Microbiol. 2012;20(1):30-39.
doi:10.1016/J.TIM.2011.10.001
15. Hurd EA, Holmén JM, Hansson GC, Domino SE. Gastrointestinal Mucins of Fut2-Null Mice Lack Terminal
Fucosylation without Affecting Colonization by Candida albicans. Glycobiology. 2005;15(10):1002.
doi:10.1093/GLYCOB/CWI089
16. Rausch P, Rehman A, Künzel S, et al. Colonic mucosa-associated microbiota is influenced by an interaction of crohn's
disease and FUT2 (Secretor) genotype. Proc Natl Acad Sci US A. 2011;108(47):19030-19035.
doi:10.1073/PNAS.1106408108/SUPPL_FILE/SD01.XLS
17. Wacklin P, Mäkivuokko H, Alakulppi N, et al. Secretor genotype (FUT2 gene) is strongly associated with the
composition of Bifidobacteria in the human intestine. PLoS One. 2011;6(5). doi:10.1371/JOURNAL.PONE.0020113
18. Mohamed JA, DuPont HL, Jiang ZD, et al. A single nucleotide polymorphism in osteoprotegerin, an anti-inflammatory
protein produced in response to infection with diarrheagenic Escherichia coli is associated with an increased risk of
non-secretory bacterial diarrhea in US travelers to Mexico. J Infect Dis. 2009;199(4):477. doi:10.1086/596319
19. Rafii F, Sutherland JB, Cerniglia CE. Effects of treatment with antimicrobial agents on the human colonic microflora.
Ther Clin Risk Manag. 2008;4(6):1343. doi:10.2147/TCRM.S4328
20. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestine
microbiota. Microbiology (Reading). 2010;156(Pt 11):3216-3223. doi:10.1099/MIC.0.040618-0
21. Shah T, Baloch Z, Shah Z, Cui X, Xia X. The Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization
Resistance, and Diseases. Int J Mol Sci. 2021;22(12):22. doi:10.3390/IJMS22126597
22. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur
J Clin Invest. 2011;41(4):380-386. doi:10.1111/J.1365-2362.2010.02419.X
23. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during
proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504-508. doi:10.1016/J.CGH.2009.12.022
24. Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health
and disease. Nat Rev Gastroenterol Hepatol. 2012;9(5):271-285. doi:10.1038/NRGASTRO.2012.57
25. Roland BC, Ciarleglio MM, Clarke JO, et al. Low ileocecal valve pressure is significantly associated with small
intestinal bacterial overgrowth (SIBO). Dig Dis Sci. 2014;59(6):1269-1277. doi:10.1007/S10620-014-3166-7
26. Scarpignato C, Barbara G, Lanas A, Strate LL. Management of colonic diverticular disease in the third millennium:
Highlights from a symposium held during the United European Gastroenterology Week 2017.
https://doi.org/101177/1756284818771305. Published online May 20, 2018. doi:10.1177/1756284818771305
27. Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health
and disease. Nat Rev Gastroenterol Hepatol. 2012;9(5):271-285. doi:10.1038/NRGASTRO.2012.57
28. Small bowel bacterial overgrowth: MedlinePlus Medical Encyclopedia. Accessed October 4, 2022.
https://medlineplus.gov/ency/article/000222.htm
29. Kilian M, Chapple ILC, Hannig M, et al. The oral microbiome - an update for oral healthcare professionals. Br Dent J.
2016;221(10):657-666. doi:10.1038/SJ.BDJ.2016.865
30. Corthésy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013;4(JUL):185.
doi:10.3389/FIMMU.2013.00185/BIBTEX
31. Eckmann L. Mucosal defenses against Giardia. Parasite Immunol. 2003;25(5):259-270. doi:10.1046/J.1365-
3024.2003.00634.X
32. Brennan CA, Garrett WS. Fusobacterium nucleatum — symbiont, opportunist and oncobacterium. Nat Rev Microbiol.
2019;17(3):156. doi:10.1038/S41579-018-0129-6
33. Zhang J, Hoedt EC, Liu Q, et al. Elucidation of Proteus mirabilis as a Key Bacterium in Crohn's Disease
Inflammation. Gastroenterology. 2021;160(1):317-330.e11. doi:10.1053/J.GASTRO.2020.09.036
34. Croswell A, Amir E, Teggatz P, Barman M, Salzman NH. Prolonged Impact of Antibiotics on Intestinal Microbial
Ecology and Susceptibility to Enteric Salmonella Infection. Infect Immun. 2009;77(7):2741. doi:10.1128/IAI.00006-09
35. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-Analysis of Antibiotics and the Risk of Community-Associated
Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326. doi:10.1128/AAC.02176-12
36. Pyleris E, Tzivras D, Barbatzas C, Giamarellos-Bourboulis EJ, Koussoulas V, Pimentel M. The prevalence of
overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel
syndrome. Dig Dis Sci. 2012;57(5):1321-1329. doi:10.1007/S10620-012-2033-7
37. Miele L, Valenza V, Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic
fatty liver disease. Hepatology. 2009;49(6):1877-1887. doi:10.1002/HEP.22848
38. Scarpellini E, Giorgio V, Gabrielli M, et al. Prevalence of small intestinal bacterial overgrowth in children with irritability
Bowel syndrome: a case-control study. J Pediatr. 2009;155(3):416-420. doi:10.1016/J.JPEDS.2009.03.033
39. Ford AC, Spiegel BMR, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome:
systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279-1286.
doi:10.1016/J.CGH.2009.06.031
40. Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its
eradication. Clin Gastroenterol Hepatol. 2008;6(7):759-764. doi:10.1016/J.CGH.2008.02.054
41. Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. Rosacea and gastrointestinal disorders: a
population-based cohort study. Br J Dermatol. 2017;176(1):100-106. doi:10.1111/BJD.1493